The Third Survey of Prescription Pattern of Psychotropic Drugs in China

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Peking University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Xian-Janssen Pharmaceutical Ltd.
Information provided by (Responsible Party):
Si Tianmei, Peking University
ClinicalTrials.gov Identifier:
NCT01668810
First received: August 16, 2012
Last updated: August 17, 2012
Last verified: July 2012
  Purpose

The investigators aimed to examine the psychotropic prescription pattern in China.


Condition
Prescription

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder

Resource links provided by NLM:


Further study details as provided by Peking University:

Estimated Enrollment: 7000
Study Start Date: July 2012
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Beijing region
include six hospitals
Guangdong Province
include 3 hospitals
Jiangsu province
include 3 hospitals
Hebei province
include 6 hospitals
Hubei Province
include 7 hospitals
Shanxi province
include 3 hospitals
Jiangxi province
include 3 hospitals
Jilin province
include 6 hospitals
Sichuan province
include 3 hospitals
Shaanxi province
include 3 hospitals

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

schizophrenia, depression and bipolar disorder patients

Criteria

Inclusion Criteria: aged 18-65, inpatient or outpatient, Patient must be willing and able to give written informed consent,the patient suffers from schizophrenia or depression or bipolar disorder -

Exclusion Criteria:aged<18or aged>65

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01668810

Contacts
Contact: Yun-Ai Su, Phd. 8610-82801960 suyunai@gmail.com

Locations
China, Beijing
Institute of mental health, Peking University Recruiting
Beijing, Beijing, China, 100191
Contact: Tianmei Si, PhD.    8610-82801960    si.tian-mei@163.com   
Principal Investigator: Tianmei Si, PhD.         
Sponsors and Collaborators
Peking University
Xian-Janssen Pharmaceutical Ltd.
Investigators
Study Chair: Xin Yu, MD. Peking University
  More Information

No publications provided

Responsible Party: Si Tianmei, Professor, Peking University
ClinicalTrials.gov Identifier: NCT01668810     History of Changes
Other Study ID Numbers: RISSCH4255
Study First Received: August 16, 2012
Last Updated: August 17, 2012
Health Authority: China: Food and Drug Administration

Keywords provided by Peking University:
prescription
schizophrenia
depression
bipolar disorder

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014